GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

gumokimab   Click here for help

GtoPdb Ligand ID: 13889

Synonyms: AK-111 | AK111
Immunopharmacology Ligand
Compound class: Antibody
Comment: Gumokimab (AK111) is a humanized IgG1 anti-IL-17A monoclonal antibody [2]. It blocks pro-inflammatory cytokine secretion mediated by the IL-17/IL-17 receptor signaling pathway. Based on heavy and light chain CDR sequence matches gumokimab is likely claimed in Akeso's patent EP3805264A1, and is most probably antibody13E9 H3L2 therein [3].
No information available.
Summary of Clinical Use Click here for help
Gumokimab (AK111) is a clinical candidate with disease modifying potential for chronic infalmmatory diseases.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05096364 A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis Phase 2 Interventional Akeso
NCT05467995 A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis Phase 2 Interventional Akeso
NCT06066125 A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis Phase 3 Interventional Akeso
NCT06378697 A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis Phase 3 Interventional Akeso
NCT05504317 A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis Phase 1 Interventional Akeso 1